Clinical Trial Update: a Study of QL1706 or QL1604 in Patients With Limited-stage Small Cell Lung Cancer After Chemoradiotherapy. [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial evaluating QL1706 or QL1604 in patients with limited-stage small cell lung cancer after chemoradiotherapy; status is not yet recruiting…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Small Cell Lung Cancer

Drugs mentioned

• QL1604
• QL1706

Snippet

Sponsor: Qilu Pharmaceutical Co., Ltd. | Conditions: Small-cell Lung Cancer | Phase 3 | Status: NOT_YET_RECRUITING